VERVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.01 USD | -5.50% |
|
-6.24% | -56.89% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,776 | 1,192 | 1,121 | 504.6 | - | - |
| Enterprise Value (EV) 1 | 1,416 | 637.2 | 497.2 | 45.83 | 277 | 504.6 |
| P/E ratio | -8.23 x | -6.65 x | -4.47 x | -2.23 x | -1.93 x | -1.79 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 614 x | 95.3 x | 45 x | 44.8 x | 24.8 x |
| EV / Revenue | - | 328 x | 42.3 x | 4.09 x | 24.6 x | 24.8 x |
| EV / EBITDA | -16.6 x | -3.91 x | -2.28 x | -0.18 x | -0.87 x | -1.34 x |
| EV / FCF | -17.2 x | -4.7 x | -3.28 x | -0.22 x | -1.21 x | -2.18 x |
| FCF Yield | -5.81% | -21.3% | -30.5% | -464% | -82.7% | -46% |
| Price to Book | 2.77 x | 1.9 x | 1.49 x | 1.37 x | 1.68 x | 1.86 x |
| Nbr of stocks (in thousands) | 48,171 | 61,604 | 80,424 | 83,965 | - | - |
| Reference price 2 | 36.87 | 19.35 | 13.94 | 6.010 | 6.010 | 6.010 |
| Announcement Date | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.941 | 11.76 | 11.22 | 11.28 | 20.38 |
| EBITDA 1 | - | -85.53 | -162.9 | -217.7 | -258.1 | -319.4 | -376.6 |
| EBIT 1 | - | -87.07 | -165.7 | -223.1 | -236.6 | -272.3 | -309.3 |
| Operating Margin | - | - | -8,536.17% | -1,897.64% | -2,109.2% | -2,415.12% | -1,517.9% |
| Earnings before Tax (EBT) 1 | - | -120.3 | -157.3 | -199.8 | -215 | -249.3 | -282.1 |
| Net income 1 | -45.7 | -120.3 | -157.4 | -200.1 | -220.7 | -257.6 | -295.3 |
| Net margin | - | - | -8,108.55% | -1,701.55% | -1,967.77% | -2,284.5% | -1,449.12% |
| EPS 2 | - | -4.480 | -2.910 | -3.120 | -2.701 | -3.116 | -3.353 |
| Free Cash Flow 1 | - | -82.24 | -135.6 | -151.7 | -212.8 | -229 | -231.9 |
| FCF margin | - | - | -6,984.23% | -1,290.47% | -1,897.48% | -2,031.49% | -1,137.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/28/21 | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.929 | 1.012 | 1.404 | 2.093 | 3.117 | 5.143 | 5.695 | 3.485 | 2.9 | 7.686 | 1.5 | 1.5 |
| EBITDA | -32.07 | - | - | -43.14 | -46.78 | - | - | -50.86 | - | -55.21 | - | - | - | - | - |
| EBIT 1 | -32.54 | -31.92 | -42.19 | -43.86 | -47.71 | -58.26 | -58.58 | -52.33 | -53.95 | -56.84 | -60.42 | -62.97 | -60.79 | -63.38 | -65 |
| Operating Margin | - | - | - | -4,721.21% | -4,714.33% | -4,149.5% | -2,799% | -1,678.99% | -1,048.98% | -998.14% | -1,733.68% | -2,171.44% | -790.98% | -4,225% | -4,333.33% |
| Earnings before Tax (EBT) 1 | -31.34 | -30.17 | -40.95 | -45.19 | -41.03 | -51.98 | -53.81 | -45.69 | -48.32 | -48.63 | -55.23 | -57.54 | -52.55 | -59.48 | -62.32 |
| Net income 1 | -31.34 | -30.17 | -40.95 | -45.19 | -41.08 | -51.98 | -53.98 | -45.76 | -48.35 | -48.74 | -55.25 | -57.56 | -52.55 | -59.53 | -62.38 |
| Net margin | - | - | - | -4,864.37% | -4,059.68% | -3,701.92% | -2,579.22% | -1,468.01% | -940.17% | -855.77% | -1,585.39% | -1,984.68% | -683.69% | -3,968.57% | -4,158.33% |
| EPS 2 | -0.6500 | -0.6200 | -0.8400 | -0.7900 | -0.6700 | -0.8400 | -0.8700 | -0.7200 | -0.6900 | -0.5900 | -0.6576 | -0.6884 | -0.7000 | -0.7500 | -0.7567 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/14/22 | 5/10/22 | 8/9/22 | 11/7/22 | 3/2/23 | 5/15/23 | 8/10/23 | 11/7/23 | 2/27/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 360 | 555 | 624 | 459 | 228 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.2 | -136 | -152 | -213 | -229 | -232 |
| ROE (net income / shareholders' equity) | - | -82% | -34.7% | -34.8% | -53.4% | -86.8% | -95.7% |
| ROA (Net income/ Total Assets) | - | -52% | -29.6% | -27.9% | -44% | -75.1% | -86.3% |
| Assets 1 | - | 231.3 | 531.7 | 716.1 | 502.1 | 343.1 | 342.3 |
| Book Value Per Share 2 | - | 13.30 | 10.20 | 9.340 | 4.370 | 3.570 | 3.230 |
| Cash Flow per Share | - | - | -2.260 | - | - | - | - |
| Capex 1 | - | 4.36 | 13.2 | 9.28 | 8.18 | 9.22 | 8.85 |
| Capex / Sales | - | - | 681.71% | 78.95% | 72.88% | 81.77% | 43.42% |
| Announcement Date | 5/28/21 | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.01
USD
Average target price
31
USD
Spread / Average Target
+415.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.89% | 505M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- VERV Stock
- Financials Verve Therapeutics, Inc.